

Contents

XI Preface

Muenke, M.; Kruszka, P.S. (Bethesda, Md.); Sable, C.A. (Washington, D.C.); Belmont, J.W. (Houston, Tex.)

XIII Foreword

Noonan, J.A. (Lexington, Ky.)

1 Overview

2 Congenital Cardiovascular Anomalies: A Historical Overview

Moller, J.H. (Minneapolis, Minn.)

- 2 Abstract
- 3 Early Descriptions of Anomalies
- 3 Correlating Anatomic and Clinical Features
- 4 Diagnostic Procedures
- 4 Extracardiac Operations
- 6 Intracardiac Operations
- 8 Interventional Catheterization Procedures
- 9 Other Advances
- 9 References

11 Normal Development of the Heart

Sylva, M.; Moorman, A.F.M. (Amsterdam)

- 11 Abstract
- 11 Formation of the Linear Heart Tube
 - 11 Origin of the Cardiac Mesoderm
- 12 Folding of the Embryo and Formation of the Heart Tube
- 12 Growth of the Linear Heart Tube
- 15 From One Tube to Four Chambers
 - 15 The Ballooning Model of Chamber Formation
 - 15 Formation of the Atrial Chambers
 - 17 Formation of the Ventricular Chambers
- 18 Building the ECG
- 18 The Earliest ECG Recordings

- 18 Sinus Node
- 18 Atrioventricular Node
- 18 Peripheral Ventricular Conduction System
- 19 Septation
 - 19 Atrial Septation
 - 19 Ventricular Septation
 - 19 Septation of the Atrioventricular Canal and Primary Foramen
- 21 Separation of the Outflow Tract
- 21 The Cardiac Connective Tissues
- 21 Development of the Cardiac Vasculature
- 21 The Insulating Plane
- 22 Development of the Valves
 - 22 Unidirectional Flow in the Primitive Heart
 - 22 The Atrioventricular Valves
 - 22 The Semilunar Valves
 - 22 Remodeling of the Embryonic Valves
- 22 Future Perspective
- 24 References

2 Epidemiology

28 Epidemiology and Prevention of Congenital Heart Defects

Botto, L.D. (Salt Lake City, Utah)

- 28 Abstract
- 29 Understanding the Problem
- 29 Common, Costly, and Critical: Epidemiology as an Incentive for Action
 - 29 How Common Are Congenital Heart Defects?
 - 30 What Drives the Variations in Reported Birth Prevalence?
 - 32 How Many People Are Living with Congenital Heart Defects – Including Adults?
 - 32 How Costly Are Congenital Heart Defects?
 - 33 Short-Term Assessment: Cross-Sectional Costs

| | | | |
|----|--|----|--|
| 34 | Long-Term View: Lifetime Costs | 72 | Cardiac Failure |
| 34 | How Critical Are Heart Defects? | 73 | Arrhythmias |
| 34 | Prevention: Evidence and Strategies | 74 | Pulmonary Hypertension |
| 35 | Integrating Interventions | 75 | Pregnancy and Delivery |
| 35 | When to Start Preventing? | 76 | Psychosocial Issues |
| 35 | What Proportion of Heart Defects Can Be Prevented? | 76 | Possibility of Acquired Cardiovascular Disease |
| 36 | Estimating How Many Cases Can Be Prevented | 77 | Aortopathy |
| 37 | Maximizing the Impact | 77 | Conclusion |
| 38 | Case Study: Maternal Diabetes | 78 | References |
| 39 | Case Study: Folic Acid/Multivitamins | | |
| 40 | Putting Everything Together: Healthy Heart, Healthy Child, and Healthy Parents | | |
| 41 | Epidemiology and Prevention: Trends and Future | | |
| 43 | Conclusions | | |
| 43 | References | | |

46 Clinical Epidemiology and Management of Congenital Heart Defects in a Developing Country

Ekure, E.N. (Lagos); Adeyemo, A.A. (Bethesda, Md.)

| | |
|----|---|
| 46 | Abstract |
| 47 | Types of Congenital Heart Defects Seen in Nigeria |
| 49 | Etiology of Congenital Heart Defects in Nigeria |
| 50 | Age at Diagnosis |
| 51 | Clinical Presentation |
| 52 | Management of Congenital Heart Defects in Nigeria |
| 54 | Outcome |
| 54 | Challenges and Opportunities |
| 55 | References |

57 Maternal Nongenetic Risk Factors for Congenital Heart Defects

Riehle-Colarusso, T.J. (Atlanta, Ga.); Patel, S.S. (Aurora, Colo.)

| | |
|----|---|
| 57 | Abstract |
| 58 | Understanding Risk Factors for Congenital Heart Defects |
| 58 | Measurements of Associations for Risk Factors with Congenital Heart Defects |
| 59 | Challenges of Studying Risk Factors for Congenital Heart Defects |
| 59 | Select Risk Factors |
| 60 | Maternal Sociodemographic Characteristics |
| 60 | Maternal Health Conditions |
| 65 | Maternal Therapeutic Medications |
| 66 | Maternal Nontherapeutic Drugs |
| 66 | Conclusion |
| 67 | References |

70 Adults with Congenital Heart Disease

Niwa, K. (Tokyo)

| | |
|----|--|
| 70 | Abstract |
| 70 | Frequency of Adult Congenital Heart Disease |
| 71 | Treatment Facilities and Human Resources |
| 72 | Current Status and Future Prospects of Adult Congenital Heart Disease |
| 72 | Common Problems and Specific Pathophysiological Issues in Adult Congenital Heart Disease |

3 Chromosomal Disorders

82 Down Syndrome

Kruszka, P.S. (Bethesda, Md.)

| | |
|----|------------------------------------|
| 82 | Abstract |
| 82 | Epidemiology |
| 83 | Genetics |
| 84 | Embryogenesis |
| 85 | Clinical Presentation |
| 85 | Cardiac Phenotype |
| 87 | Treatment |
| 88 | Prognosis |
| 88 | Gene Therapy for Future Directions |
| 88 | References |

91 Congenital Cardiovascular Defects in Monosomy X or Turner Syndrome

Bondy, C. (Bethesda, Md.)

| | |
|----|---|
| 91 | Abstract |
| 92 | Spectrum of Congenital Cardiovascular Malformations in Turner Syndrome |
| 92 | Aortic Valve |
| 93 | Aortic Dilation |
| 93 | Aortic Arch |
| 94 | Partial Anomalous Pulmonary Venous Return |
| 94 | Other Cardiovascular Defects |
| 94 | Theories on the Cause of Congenital Cardiovascular Defects in Turner Syndrome |
| 94 | Association with Fetal Lymphedema |
| 95 | Neural Crest |
| 95 | Parallels with the 22q11.2 Deletion (DiGeorge Syndrome) |
| 96 | Genes Implicated in Turner Syndrome |
| 97 | X-Chromosome Genomic Imprinting |
| 97 | Conclusion |
| 97 | References |

100 The 22q11.2 Deletion Syndrome

Goldmuntz, E. (Philadelphia, Pa.)

| | |
|-----|--|
| 100 | Abstract |
| 101 | Molecular Characteristics of the 22q11.2 Deletion Syndrome |
| 101 | Clinical Characteristics of the 22q11.2 Deletion Syndrome |
| 101 | Congenital Heart Disease in the 22q11.2 Deletion Syndrome |

| | |
|------------|--|
| 103 | Noncardiac Manifestations of the 22q11.2 Deletion Syndrome |
| 104 | The 22q11.2 Deletion Syndrome and Congenital Heart Disease |
| 104 | 22q11.2 Deletions in Conotruncal Defects |
| 105 | Identifying the Cardiac Patient with a 22q11.2 Deletion |
| 106 | Clinical Outcome |
| 108 | Clinical Management of the Cardiac Patient with a 22q11.2 Deletion |
| 108 | References |
| 112 | Other Genomic Disorders Causing Congenital Cardiovascular Malformations |
| | Lalani, S.R. (Houston, Tex.) |
| 112 | Abstract |
| 114 | Genomic Rearrangements |
| 114 | Copy Number Variations in Congenital Cardiovascular Malformations |
| 115 | 1p36 Deletion |
| 115 | 8p23.1 Deletion/Duplication |
| 115 | Williams-Beuren Syndrome |
| 115 | Kleefstra Syndrome |
| 116 | Smith-Magenis Syndrome/Potocki-Lupski Syndrome |
| 116 | Koolen-de Vries Syndrome |
| 116 | Wolf-Hirschhorn Syndrome |
| 117 | Jacobsen Syndrome |
| 117 | Other Genomic Rearrangements |
| 117 | Less Frequent CVM-Associated Genomic Disorders |
| 118 | Conclusion |
| 118 | References |

4 Single Gene Disorders

| | |
|------------|--|
| 122 | Noonan Syndrome and Other RAS/MAPK Pathway Syndromes |
| | Gelb, B.D. (New York, N.Y.); Roberts, A.E. (Boston, Mass.); Tartaglia, M. (Rome) |
| 122 | Abstract |
| 123 | RASopathy-Associated Cardiovascular Involvement |
| 123 | The Noonan Syndrome |
| 125 | The Noonan Syndrome with Multiple Lentigines |
| 125 | The Cardiofaciocutaneous Syndrome |
| 125 | The Costello Syndrome |
| 126 | The Noonan Syndrome with Loose Anagen Hair |
| 126 | RASopathy Genetics |
| 127 | Genotype-Phenotype Associations |
| 127 | Pathogenesis of Cardiovascular Disease in the RASopathies |
| 127 | The Noonan Syndrome |
| 128 | The Noonan Syndrome with Multiple Lentigines |
| 128 | The Costello Syndrome |
| 128 | Concluding Remarks |
| 128 | Acknowledgments |
| 128 | References |

131 The Holt-Oram Syndrome and Other Transcription Factor-Related Heart Diseases

Borlak, J. (Hannover); Ciribilli, Y. (Mattarello)

| | |
|------------|---|
| 131 | Abstract |
| 131 | The Holt-Oram Syndrome |
| 132 | Transcription Factors and Embryogenesis |
| 134 | Germline Mutations |
| 136 | Somatic Mutations |
| 138 | Gene Reporter Assays to Evaluate the Clinical Significance of Mutations |
| 139 | 'Isogenic Nature' |
| 140 | 'Chromatin Environment' |
| 140 | 'Reporter Constructs' |
| 141 | 'Rheostatable Promoters' |
| 141 | 'Mutant Protein Assays' |
| 142 | Conclusion |
| 142 | References |
| 145 | CHARGE Syndrome |
| | Corsten-Janssen, N.; van Ravenswaaij-Arts, C.M.A. (Groningen) |
| 145 | Abstract |
| 146 | Diagnosis |
| 146 | Clinical Diagnosis |
| 147 | Molecular Diagnosis |
| 148 | Other Causes of the CHARGE Syndrome |
| 149 | Broad Phenotypic Spectrum of CHD7 Mutations |
| 149 | Clinical Features of Patients with a CHD7 Mutation |
| 149 | CHD7 Mutations in Other Syndromes |
| 149 | Genotype-Phenotype Associations |
| 150 | Heart Defects in the CHARGE Syndrome |
| 151 | CHD7 Function in the Heart |
| 152 | Clinical Surveillance and Genetic Counseling |
| 152 | Concluding Remarks |
| 153 | References |

155 Alagille Syndrome

Lin, H.C.; Falsey, A.; Krantz, I.; Spinner, N. (Philadelphia, Pa.)

| | |
|-----|--------------------------------|
| 155 | Abstract |
| 156 | Pathophysiology |
| 156 | Clinical Features |
| 157 | Hepatic Manifestations |
| 158 | Cardiac Manifestations |
| 159 | Musculoskeletal Manifestations |
| 159 | Ocular Manifestations |
| 160 | Facial Features |
| 160 | Renal Manifestations |
| 161 | Vascular Manifestations |
| 161 | Cognitive Function |
| 161 | Diagnosis |
| 162 | Management |
| 163 | Genetic Counseling |
| 163 | Conclusion |
| 163 | References |

| | |
|---|---|
| 166 Heterotaxy | Lo, C.; Li, Y.; Yagi, H.; Gabriel, G.; Klena, N.; Lemke, K. (Pittsburgh, Pa.); Leatherbury, L. (Washington, D.C.) |
| 166 Abstract | |
| 168 Classification of Heterotaxy: Atrial Isomerisms and Other Laterality Defects | |
| 169 Association of Complex Congenital Heart Disease with Heterotaxy | |
| 169 Left-Right Patterning and Regulation of Cardiac Looping | |
| 171 Genetic Etiology of Heterotaxy | |
| 171 Ciliopathies and Heterotaxy | |
| 172 Airway Cilium Dysfunction Associated with Primary Ciliary Dyskinesia and Heterotaxy | |
| 172 Respiratory Symptoms and Disease in Ciliopathy and Heterotaxy Patients | |
| 173 Respiratory Complications and Worse Outcome in Heterotaxy Patients | |
| 173 Summary and Future Prospects for Improving Clinical Care and Outcome | |
| 175 Acknowledgments | |
| 175 References | |
| 178 Molecular Genetics of Isolated Cardiovascular Malformations | Lee, T.M.; Chung, W.K. (New York, N.Y.) |
| 178 Abstract | |
| 179 Monogenic Cardiovascular Malformations | |
| 179 Atrial Septal Defects | |
| 181 Ventricular Septal Defects | |
| 181 Bicuspid Aortic Valves | |
| 181 Supravalvar Aortic Stenoses | |
| 181 Additional Lesions | |
| 182 Recent Advances | |
| 182 Copy Number Variants | |
| 182 De novo Variants | |
| 182 Genome-Wide Association Studies | |
| 182 Clinical Genetic Evaluation and Testing | |
| 183 Conclusion | |
| 183 References | |
| 186 Other Single-Gene Disorders Causing Congenital Heart Disease | Russell, M.W.; Hannibal, M. (Ann Arbor, Mich.) |
| 186 Abstract | |
| 186 VACTERL Association | |
| 187 Diagnosis/Evaluation | |
| 187 The Kabuki Syndrome | |
| 188 Diagnosis/Evaluation | |
| 188 The Ellis-van Creveld Syndrome | |
| 189 Diagnosis/Evaluation | |
| 189 The Cornelia de Lange Syndrome | |
| 190 Diagnosis/Evaluation | |
| 190 The Mowat-Wilson Syndrome | |
| 190 Diagnosis/Evaluation | |
| 190 The Smith-Lemli-Opitz Syndrome | |
| 191 Diagnosis/Evaluation | |
| 191 Treatment | |
| 191 The Rubinstein-Taybi Syndrome | |
| 192 Diagnosis/Evaluation | |
| 192 The Char Syndrome | |
| 193 Diagnosis/Evaluation | |
| 193 The Goldenhar Syndrome | |
| 193 Diagnosis/Evaluation | |
| 193 Conclusion | |
| 193 Acknowledgments | |
| 194 References | |
| 5 Arrhythmias, Cardiomyopathies, and Connective Tissue Disorders | |
| 198 Genetic Arrhythmias (Channelopathies) | Mazzanti, A.; Ng, K. (Pavia); Priori, S.G. (Pavia/New York, N.Y.) |
| 198 Abstract | |
| 199 Long QT Syndrome | |
| 199 Epidemiology | |
| 199 Genetic Variants | |
| 199 Diagnosis | |
| 201 Clinical Manifestations | |
| 201 Risk Stratification | |
| 202 Management | |
| 202 Short QT Syndrome | |
| 202 Epidemiology | |
| 202 Genetic Variants | |
| 203 Diagnosis | |
| 203 Clinical Manifestations | |
| 203 Risk Stratifications and Management | |
| 204 Brugada Syndrome | |
| 204 Epidemiology | |
| 204 Genetic Variants | |
| 204 Diagnosis | |
| 204 Clinical Manifestations | |
| 205 Risk Stratification | |
| 205 Management | |
| 206 Catecholaminergic Polymorphic Ventricular Tachycardia | |
| 206 Epidemiology | |
| 206 Genetic Variants | |
| 206 Diagnosis | |
| 207 Clinical Manifestations | |
| 207 Risk Stratifications | |
| 207 Management | |
| 208 Conclusions | |
| 208 References | |
| 210 Genetic Cardiomyopathies | Towbin, J.A. (Memphis, Tenn.) |
| 210 Abstract | |
| 211 Final Common Pathways | |
| 211 Dilated Cardiomyopathy | |
| 212 Genetics of Dilated Cardiomyopathy | |
| 216 Muscle Is Muscle: Cardiomyopathy and Skeletal Myopathy Genes Overlap | |
| 216 Hypertrophic Cardiomyopathy | |

| | |
|-----|---|
| 216 | Gene Identification in Familial Hypertrophic Cardiomyopathy |
| 217 | Genotype-Phenotype Correlation in Hypertrophic Cardiomyopathy |
| 218 | Restrictive Cardiomyopathy |
| 218 | Genetics |
| 218 | Left-Ventricular Noncompaction Cardiomyopathy |
| 219 | Genetics |
| 220 | Arrhythmogenic Cardiomyopathies |
| 220 | Genetics |
| 222 | Conclusions |
| 222 | References |

226 Congenital Thoracic Aortic Aneurysm

Lindsay, M.E. (Boston, Mass.);
Dietz, H.C. (Baltimore, Md.)

| | |
|-----|---------------------------------------|
| 226 | Abstract |
| 227 | Gene Discovery |
| 229 | Inheritance and Genetic Counseling |
| 230 | Clinical Findings and Diagnoses |
| 232 | Management and Molecular Pathogenesis |
| 233 | Conclusions |
| 234 | References |

6 Evaluation

238 The Genetic Workup for Congenital Structural Heart Disease: From Clinical to Genetic Evaluation

Kruszka, P.S. (Bethesda, Md.); Sable, C.A. (Washington, D.C.); Belmont, J.W. (Houston, Tex.); Muenke, M. (Bethesda, Md.)

| | |
|-----|---|
| 238 | Abstract |
| 240 | Genetic Testing Algorithm |
| 248 | Aneuploidy |
| 248 | Copy Number and Structural Variants |
| 250 | Targeted Gene Sequencing |
| 252 | Whole Genome and Whole Exome Sequencing |
| 254 | Genetic Counseling |
| 254 | Concluding Remarks |
| 254 | References |

257 Imaging of Congenital Heart Defects for the Noncardiologist

Sable, C.A. (Washington, D.C.)

| | |
|-----|---|
| 257 | Abstract |
| 257 | Types of Imaging |
| 257 | Ultrasound Physics |
| 259 | Echocardiography Examination |
| 260 | Echocardiography Logistics: Why, When, Where, Who |
| 260 | Indications |
| 260 | Timing of Imaging |
| 260 | Where/Who Does the Echocardiography |
| 261 | Common Lesions |
| 261 | Atrial Septal Defects |

| | |
|-----|---------------------------------|
| 262 | Ventricular Septal Defects |
| 264 | Atrioventricular Septal Defects |
| 265 | Tetralogy of Fallot |
| 266 | Pulmonary Valve Stenosis |
| 267 | Concluding Remarks |
| 268 | References |

269 Prenatal Evaluation of Congenital Heart Defects and Fetal Intervention

Weinberg, J.G.; Krishnan, A. (Washington, D.C.)

| | |
|-----|---|
| 269 | Abstract |
| 269 | Indications for Fetal Cardiac Evaluation |
| 270 | Timing and Performance of Fetal Echocardiography |
| 271 | Prenatal Diagnosis of Congenital Heart Defects Associated with Specific Genetic Defects |
| 271 | Fetal Intervention |
| 275 | Importance of Fetal Diagnosis and Outcomes following Prenatal Detection of Congenital Heart Defects |
| 276 | References |

7 Treatment

280 Surgical Management

Costello, J.P.; Jonas, R.A.; Nath, D.S. (Washington, D.C.)

| | |
|-----|---|
| 280 | Abstract |
| 280 | Trisomy 21 – Down Syndrome |
| 283 | The 22q11.2 Deletion – DiGeorge Syndrome |
| 284 | Trisomy 13 (Patau Syndrome) and Trisomy 18 (Edwards Syndrome) |
| 285 | Marfan Syndrome |
| 285 | Turner Syndrome |
| 285 | Noonan Syndrome |
| 286 | Other Syndromes |
| 286 | Special Considerations |
| 287 | References |

289 Interventional Cardiology

Morgan, G.J.; Qureshi, S.A. (London)

| | |
|-----|---|
| 289 | Abstract |
| 289 | Interventional Cardiac Catheterisation in Paediatric Cardiology |
| 289 | Neonatal Intervention |
| 290 | Atrial Septostomy |
| 290 | Aortic Valvoplasty |
| 291 | Pulmonary Valvoplasty |
| 292 | Infant and Paediatric Procedures |
| 292 | Atrial Septal Defect Occlusion |
| 293 | Ventricular Septal Defect Occlusion |
| 294 | Transcatheter Pulmonary Valve Implantation |
| 294 | Coarctation Stent Implantation |
| 295 | Stent Technology |
| 295 | Fetal Interventions |
| 295 | Hybrid Techniques |
| 296 | Hybrid Palliation of Hypoplastic Left Heart Disease |
| 296 | Muscular Ventricular Septal Defect Closure |
| 297 | Paravalvar Leak Occlusion |

| | | | |
|-----|--|-----|--|
| 297 | Conclusion | 307 | Tissue-Forming Cell Population |
| 297 | References | 308 | Mechanical Load and Electrical Stimulation |
| 298 | Ethical Considerations in Congenital Heart Disease | 308 | Bioreactors – A Breeding Ground for Engineered Heart Tissue |
| | Boss, R.D.; Shapiro, M.C. (Baltimore, Md.) | 309 | Current Challenges for Engineered Heart Tissue Production |
| 298 | Abstract | 309 | Cardiomyocyte Maturation |
| 299 | Social Justice and Congenital Heart Disease Risk | 310 | Host Immune Response |
| 299 | Prenatal Diagnosis: Promises and Harms | 310 | Ischemia within Engineered Heart Tissue |
| 300 | A Life Worth Living – Can We Agree? | 310 | Decellularized Heart as an Artificial Scaffold for Engineered Heart Tissue |
| 301 | Survivors of Congenital Heart Disease and Demand for Destination Therapies | 311 | Stem Cells in Engineered Heart Tissue |
| 302 | Palliative Care – Clinicians’ Personal Choices versus Professional Recommendations | 312 | Reentry of Mature Cardiomyocytes into the Cell Cycle |
| 303 | Conclusions | 313 | Novel Possibilities for Treating Hypertrophic Cardiomyopathy |
| 303 | References | 313 | Gene Therapy as Early Intervening Strategies |
| 306 | The Future of Therapeutics: Stem Cells, Tissue Plasticity, and Tissue Engineering | 314 | Perspectives |
| | Tao, G.; Martin, J.F. (Houston, Tex.) | 314 | References |
| 306 | Abstract | 317 | Author Index |
| 306 | Cardiac Tissue Engineering | 318 | Subject Index |
| 307 | Supportive Matrix in Favor of Tissue Formation | | |